Artificial Intelligence (AI) in Life Sciences Market Size, Report By 2032

Prathamesh

4 weeks ago

The global artificial intelligence (AI) in life sciences market size surpassed US$ 1.79 billion in 2023 and is projected to reach around US$ 9.17 billion by 2032 with a CAGR of 19.90% from 2023 to 2032.

The rising technological advances and rapid emergence of the novel technologies like artificial intelligence and its rising applications across various industries has led to the increased demand for the AI in the life sciences industry. The rising need for controlling costs and enhancing the operational efficiencies in the drug discovery and clinical trials is fostering the growth of the AI in life sciences market across the globe.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1776

The rapidly emerging data based AI, technological advances in the deep learning, and growing need for achieving autonomy in robotics are expected to boost the demand for the AI technology in the life sciences industry. The inefficiency of the drug discovery process due to factors such as high costs of research and development, low success rate in clinical trials, and growing focus on rare diseases is fueling the adoption of the AI in life sciences to improve efficiency and reduce costs. The machine learning technology can enhances the candidate recruitment functions, data, storage, and data analytics, which is anticipated to fuel the market growth during the forecast period.

Report Highlights

By offering, the software segment dominated the market, owing to the rising adoption of the software among the life science companies. This is attributed to the rising importance and need for data collection, processing, management, and analytics. The software can offer various benefits related to the data.
By deployment, the cloud segment dominated the market. The rising penetration of internet and rising advances in the IT and telecommunications industry has led to the development of advanced cloud based servers that can improve the operations of the organization as per their requirements and can easily store, manage, and share data.
Based on application, the drug discovery segment dominated the market owing to the rising adoption of Ai in the drug discovery process. The AI can efficiently control costs and improve the operational efficiency in the drug discovery activities.

Regional Snapshot

North America led the global AI in life sciences market. US was the major driver of the North America AI in life sciences market in 2021. The US is known to be the home of the several leading biotech and pharma companies that are the major investors in the research and development, drug discovery, and clinical trial activities. The increased demand for the AI technology among the research organizations and the pharmaceutical companies has led to the dominance of North America in the AI in life sciences market. Approximately US$80 billion was invested on research and development by the pharmaceutical companies in 2018 across the globe, as per the data of Pharmaceutical Research and Manufacturers of America (PhRMA). US leads the globe in terms of new drug discovery and development and it holds the property rights of the majority of the drugs that has been recently developed.

Asia Pacific is the home to several top research organizations that are the major drivers of the AI in life sciences market in Asia Pacific. The presence of top research institutions and rising investments in the research studies of various diseases and its treatment has bolstered the demand for the AI hardware and software in Asia Pacific region. The growing government investments towards advancing the medical infrastructure and rising pharma FDIs in the region is expected to boost the growth of the market in the forthcoming years.

Table of Contents

Toggle

Report Scope of the Artificial Intelligence (AI) in Life Sciences Market

Report Coverage	Details
Market Size by 2032	USD 9.17 Billion
Growth Rate from 2023 to 2032	CAGR of 19.90%
Largest Market	North America
Fastest Growing Region	Europe
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Offering, Deployment, Application, Geography

Artificial Intelligence (AI) in Life Sciences Market Dynamics

Driver

Growing need for clinical trials and drug discovery

Drug discovery and clinical trials are expensive affairs that involve huge recurring costs. The research, development, candidate recruitment, candidate retention, and various phases of clinical trials, each of them are very costly and the low success rate of these activities increases the costs for the company at a significant level. As per the Pharmaceutical Research and Manufacturers of America (PhRMA), the pharma companies spends around 19 % of their revenue, on an average, in the research. Therefore, the growing the growing need for controlling costs and improving outcomes is boosting the adoption of AI in life sciences field.

Restraints

Huge capital investments

The artificial intelligence is an expensive and latest technology that has gained a rapid traction across the globe and across various industry verticals. The rising need for data analytics, deep learning, machine learning, and natural language processing are the major drivers of the AI technology. However, the high capital investments in the deployment of AI in the life sciences companies may hinder the market growth during the forecast period.

Opportunity

Lack of AI experts

AI is a new technology and there is a dearth of experts and skilled staffs that can efficiently handle the AI based software and hardware systems. This automatically increases the third party services provided by the AI in life sciences market players, which increases the revenues of the AI in life sciences market players. This factor is offering the market players to generate huge revenues on recurring basis.

Challenge

Data privacy and cybersecurity

With the growing adoption of the digital technologies, the risks of malware and cyberattacks has significantly increased across the globe. The growing number of cyberattacks and rising concerns regarding the data privacy is the major challenge for the market players.

Key Market Developments

In September 2020, Pharmaspectra and IBM Watson Health announced to enter into a strategic collaboration. The new collaboration between the two companies was aimed to streamline the product portfolio of IBM Watson health by increasing its focus towards innovations and new strategies that help and support life science’s clients of the IBM using digital transformation.
In July 2020, NuMedii Inc. introduced the world’s first atlas of single-cell sequencing for idiopathic pulmonary fibrosis (IPF)with the help of a strategic collaboration for research with Yale School of Medicine, Brigham & Women’s Hospital, and Baylor College of Medicine. The new research was targeted to enhance the understanding of lungs fibrosis by using AI.
In June 2020, The University of Kentucky entered into a research collaboration with Atomwise, a leading user of artificial intelligence (AI) for small molecule discovery, to explore potential therapies for COVID-19 disease.
In March 2020, IBM and EBSCO entered into a strategic collaboration to improve the clinical decision support for the healthcare providers and health systems.

Some of the prominent players in the global AI in life sciences market include:

IBM Corporation
Atomwise, Inc.
Nuance Communications, Inc.
NuMedii, Inc.
AiCure LLC.
APIXIO, Inc.
Insilico Medicine, Inc.
Enlitic, Inc.
Sensely, Inc.
Zebra Medical Vision

Segments Covered in the Report

By Offering

Software
Hardware
Services

By Deployment

On Premise
Cloud

By Application

Medical Diagnosis
Drug Discovery
Precision and Personalized Medicine
Biotechnology
Clinical Trials
Patient Monitoring

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa